| Literature DB >> 26437718 |
Takashi Yamada1, Kimiaki Hattori2, Hidetoshi Satomi3, Yoshinobu Hirose4, Go Nakai5, Atsushi Daimon6, Atsushi Hayashi7, Yoshito Terai8, Masahide Ohmichi9, Masaharu Fukunaga10.
Abstract
BACKGROUND: The ovarian cellular fibrous tumor with mitotic figure >4 per 10 high power field without moderate to severe atypia is defined as mitotically active cellular fibroma according to the 2014 World Health Organization classification. As this category is new and rare now, we described here a case of MACF and reviewed the literature. CASE: We present a case of mitotically active cellular fibroma of the ovary with 10-year history that was treated with laparoscopic surgery.Entities:
Mesh:
Year: 2015 PMID: 26437718 PMCID: PMC4595272 DOI: 10.1186/s13048-015-0191-x
Source DB: PubMed Journal: J Ovarian Res ISSN: 1757-2215 Impact factor: 4.234
Fig. 1MRI appearance of the tumor. Axial T2-weighted MR image showed a well-circumscribed mass (white arrows) including cystic component (arrowhead) adjacent to the right ovary (black arrow) as having inhomogeneous low signal intensity. Small amount of ascites was noted (*)
Fig. 2Laparoscopic findings of the tumor. The tumor (white arrows) in the Douglas pouch protruded from right ovary (black arrow) without adhesion
Fig. 3Macroscopic appearance of resected right oophorosalpinx. The sectioned surface of the tumor was solid and light-yellow without hemorrhagic necrosis. (right ovary: black arrow)
Fig. 4Macroscopic appearance of the tumor. The cells are spindle shaped and arranged in intersecting bandles. (bar = 200 μm)
Fig. 5Macroscopic appearance of the tumor. The cells having spindled to ovoid shaped nuclei with moderate mitotic rate (mitoses: white arrows) but without significant nuclear atypia. (bar = 50 μm)
Cases of mitotically active cellular fibroma of the ovary
| Author | Year | Case no. | Age (y) | Side | Size(cm) | Tumor marker | Mitoses (MF/10HPF) | Surgery | Additional therapy | Positive | Weak, focally | Negative | ki-67 index | Follow-up time (mo) | Status at last follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kaku et al. [ | 2007 | 1 | 32 | Left | 6.6 × 6,0 × 4.4 | CA 125(-), CEA(-) | 17 | LSO | - | SMA, HHF35, vimentin, PR, ki-67 | ER | desmin | ND | 12 | NED |
| Bucella et al. [ | 2009 | 2 | 65 | ND | 10(1st), 12 × 10 × 9 (2nd), 8 (3rd) | - | 4 | TAH, BSO, reduction twice | Tamoxifen | vimentin | α-inhibin, actin, CD99 | desmin, h-caldesmon, CD10, HMB-45, c-kit | 9 | 60 + 6 + 6 | Recurrence twice, NED |
| Monterio et al. [ | 2012 | 3 | 13 | Right | 19 × 15 × 12 | CA125(453), AFP(-), HCG(-), CEA(-), CA199(-), CA153(-) | 5–7 | RSO, OMT | - | ND | ND | ND | ND | 36 | NED |
| Wu et al. [ | 2014 | 4 | 76 | Right | 9 × 6 × 5 | CA125(-), CA153(-), CA199 (-),AFP (-), CEA(-), SCC(-) | 5–9 | TAH, BSO | - | vimentin, α-inhibin, ER, PR | CD56, CD99 | cytokeratin, EMA, CD10, HMB45, S-100, calretinin, CD34, CD117, Dog-1 | 10 | ND | ND |
| Zong et al. [ | 2014 | 5 | 39 | Left | 10 × 7 × 4 | CA125(41), HCG(-) | 3–5 | TAH, LSO, OMT, LD | - | CD99, CK, SMA, vimentin, ER, PR, S-100 | - | CD10, CK7, EMA, desmin | 10 | 66 | NED |
| This case | 2015 | 6 | 36 | Right | 6 | CEA(-), CA125(-), CA199(-), SCC(-), HCG(-), AFP(-) | 10 | RSO | - | vimentin, PR, CD10, CD56, WT1 | α-inhibin | AE1/AE3, ER, calretinin, EMA | 8.7 | 6 | NED |
ND, not described; CEA, carcinoembryonic antigen; (-), within normal range; AFP, α-feto protein; HCG, human chorionic gonadotropin; SCC, squamous cell carcinoma; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; OMT, omentectomy; LD, lymphadenectomy; SMA, smooth muscle actin; HHF35, anti-muscle-specific actin (clone; HHF35); PR, progresterone receptor; ER, estrogen receptor; CK, cytokeratin; WT, Wilms tumor; HMB, human melanoma black; EMA, epithelial membrane antigen; NED, no evidence of the diseade